Skip to main content
Signal8

abrdn Life Sciences Investors (HQL)

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.

Industry: Asset Management

Tekla Life Sciences Investors logo

Tekla Life Sciences Investors

NYSE:HQLFinancial Services
-1.23%$17.73
AH Close$17.73+0.00%vs close
Mkt Cap$539.13M
Float30.41M
O/S30.41M
Inst Own25.9%
Div Yield12.63%
Dilution
FormDescription
13G/A
Beneficial Ownership Report (Amended)
40-17G
SEC Filing
NPORT-P
SEC Filing
N-PX
SEC Filing
4
OWNERSHIP DOCUMENT
3
OWNERSHIP DOCUMENT
N-CSRS
SEC Filing
NPORT-P
SEC Filing
DEF 14A
Definitive Proxy Statement
13G/A
Beneficial Ownership Report (Amended)
NPORT-P
SEC Filing
13D/A
Beneficial Ownership Report (Active, Amended)
13D/A
Beneficial Ownership Report (Active, Amended)
13D/A
Beneficial Ownership Report (Active, Amended)
3
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
N-CSR
SEC Filing
N-CEN
SEC Filing
NPORT-P
SEC Filing
13D/A
Beneficial Ownership Report (Active, Amended)
13D/A
Beneficial Ownership Report (Active, Amended)
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT
4
PRIMARY DOCUMENT

1-25 of 519

…
    abrdn Life Sciences Investors (HQL) SEC Filings: 10-K, 10-Q, 8-K, Form 4 | Signal8